Orphazyme is delighted to announce that Dr Thomas Blaettler will become the company's new Chief Medical Officer.
Dr Blaettler, MD, is a certified neurologist with extensive clinical development and leadership experience, most recently from Roche where he headed a late-stage programme in rare disease indication spinal muscular atrophy. Dr Blaettler says “I am thrilled about the prospect of advancing Orphazyme's innovative medicines through well designed clinical studies to patients in great need of treatment. I look forward to joining the Orphazyme team to successfully deliver on the AIDNPC programme in Niemann-Pick disease type C as well as to set up clinical development programmes in other debilitating and life-shortening lysosomal storage disorders that today lack effective treatment.”
Anders Hinsby, CEO of Orphazyme ApS, says: “The whole team at Orphazyme has been working tirelessly to bring our technology and scientific advancements from the laboratory into the clinic. With Thomas Blaettler now on board, we will be well equipped to design and implement long-term clinical strategies, fulfilling our aim to improve the lives of those suffering with rare, and often fatal, diseases.”
Orphazyme ApS is a Danish biopharmaceutical company which develops paradigm-changing medicines for the treatment of genetic diseases. The lead program is in development as a treatment for lysosomal storage diseases. This family of genetic disorders consisting of more than 45 diseases, including Niemann-Pick disease type C, often affect children; most of whom are currently untreatable. Orphazyme’s AIDNPC study is a phase III clinical trial to investigate a novel treatment for Niemann-Pick disease type C, which launched in July 2016 (www.ADINPC.com). Orphazyme is backed by leading European VCs. The strong investor syndicate includes Novo A/S, Sunstone Capital, Aescap Venture, Kurma Partners and Idinvest Partners. For more information, visit www.orphazyme.com.
Anders Hinsby, CEO of Orphazyme